You have reached the HIVandHepatitis.com legacy site. Please visit our new site at hivandhepatitis.com
HIV and Hepatitis.com Coverage of the
45th Annual Meeting of the European
Association for the Study of the Liver (EASL 2010)
 April 14 - 18, 2010, Vienna, Austria
  The material posted on HIV and Hepatitis.com about EASL 2010 is not approved by nor is it a part of EASL 2010.
Library of Slides and Posters
Hepatitis B Articles
Hepatitis C Articles
Coinfection Articles
    Google Custom Search
This program will be of interest to healthcare providers
who provide care to patients with hepatitis B
 
Hepatitis B Articles
Longer Treatment with Pegylated Interferon Works Better for Hepatitis B Genotype D
Tenofovir (Viread) Effective for Treatment of Chronic Hepatitis B Patients with Suboptimal Response to Adefovir (Hepsera)
Telbivudine (Tyzeka) Produces Better Outcomes than Lamivudine in Hepatitis B Patients with Decompensated Cirrhosis
HBV DNA and HBsAg Levels Predict Likelihood of Sustained Response to Pegylated Interferon for Hepatitis B
MARS and Prometheus Artificial Liver Devices Offer Some Benefits for Patients with Liver Failure, but Did Not Improve Survival
Tenofovir (Viread) Demonstrates High Barrier to Resistance over 3 Years in Chronic Hepatitis B Patients
EASL International Liver Congress Presents New Data on Hepatitis B and C Pathogenesis and Treatment
World Hepatitis Alliance Releases Major Report on Viral Hepatitis Policy at EASL Meeting
Tenofovir/emtricitabine (Truvada) Prevents Hepatitis B Recurrence after Liver Transplantation in Patients with Mild Kidney Impairment
Prior Non-responders Achieve Treatment Success with Telaprevir plus Pegylated Interferon and Ribavirin
Tenofovir (Viread) Demonstrates High Barrier to Resistance over 3 Years in Chronic Hepatitis B Patients
Hepatitis C Articles
Nitazoxanide Increases Response to Pegylated Interferon plus Ribavirin in Treatment-naive and Non-responder Hepatitis C Patients
Rifaximin Reduces Encephalopathy Recurrence, Improves Quality of Life in People with Liver Cirrhosis
Many Genotype 1 Hepatitis C Patients Can Be Cured with 24 Weeks of Telaprevir plus Pegylated Interferon/ribavirin
Combination of 2 Nucleotide HCV Polymerase Inhibitors, PSI-7977 and PSI-938, Looks Good in Laboratory Study
Measurable Neurocognitive Impairment Signals Hepatic Encephalopathy in People with Liver Cirrhosis
Women More Likely to Die while Awaiting Liver Transplants under the MELD Allocation System
PROTECT Study Finds One-third of Liver Transplant Patients Achieve Sustained Response to Pegylated Interferon plus Ribavirin
HCV Polymerase Inhibitor IDX184, Protease Inhibitor IDX320, and Triple Combination Show Promising Antiviral Activity
HCV NS5A Inhibitor BMS-790052 Suppresses Viral Replication in Combination with Pegylated Interferon/ribavirin
Cyclophilin Inhibitor SYC-635 May Reduce Fibrosis in Addition to Inhibiting Hepatitis C Virus Replication
Experimental HCV Polymerase Inhibitor RG7128 Is Effective with Standard Therapy in Genotype 2/3 Patients
HCV Therapeutic Vaccine GI-5005 Improves Rate of Sustained Response to Interferon-based Therapy for Hepatitis C
MARS and Prometheus Artificial Liver Devices Offer Some Benefits for Patients with Liver Failure, but Did Not Improve Survival
Closely Individualized Treatment with Pegylated Interferon plus Ribavirin Is Possible Based on Baseline Viral Load and Early Response
Gilead Terminates Study of Caspase Inhibitor GS 9450 for Hepatitis C Due to Safety Concerns
Experimental HCV Protease Inhibitor BI 201335 Shows Robust Antiviral Activity in Genotype 1 Non-responders
World Hepatitis Alliance Releases Major Report on Viral Hepatitis Policy at EASL Meeting
Closely Individualized Treatment with Pegylated Interferon plus Ribavirin Is Possible Based on Baseline Viral Load and Early Response
Gilead Terminates Study of Caspase Inhibitor GS 9450 for Hepatitis C Due to Safety Concerns
Experimental HCV Protease Inhibitor BI 201335 Shows Robust Antiviral Activity in Genotype 1 Non-responders
HCV Protease Inhibitor Danoprevir (RG7227/ITMN-191) Shows Antiviral Activity at Lower Doses When Boosted with Ritonavir
HCV Polymerase Inhibitor VX-222 Demonstrates Good Safety and Antiviral Activity in Treatment-naive Genotype 1 Hepatitis C Patients
EASL International Liver Congress Presents New Data on Hepatitis B and C Pathogenesis and Treatment
HCV Protease Inhibitor Boceprevir Demonstrates Durable Sustained Response with No Late Relapse
Prior Non-responders Achieve Treatment Success with Telaprevir plus Pegylated Interferon and Ribavirin
 
Coinfection Articles
Pegylated Interferon plus Ribavirin Works as Well in HIV/HCV Coinfected Patients with Cirrhosis
Screening for Liver Cancer in HIV/HCV Coinfected People
European Study Finds More than Half of HIV/HCV Coinfected Patients Do Not Receive Treatment despite Advanced Fibrosis
HIV/HCV Coinfected Patients with Acute Hepatitis C Are Equally Likely to Achieve Sustained Response with Interferon plus Ribavirin
HIV and Hepatitis C Virus Coinfection May Increase Death of CD4 T-cells
Child-Pugh Score Changes Do Not Predict Liver Failure among HIV/HCV Coinfected Patients during Hepatitis C Treatment
Response to Interferon-based Therapy Is Lower in HIV/HCV Coinfected Patients than HCV Monoinfected, but Predicted by Similar Factors
Biopsy Study Suggests Liver Disease Does Not Progress Faster in HIV/HCV Coinfected People

EASL 2010 - EASL Coverage - EASL NEWS - International Liver Congess 2010

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

CROI 2010 Coverage